<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155608</url>
  </required_header>
  <id_info>
    <org_study_id>NIMH R34MH101282</org_study_id>
    <secondary_id>R34MH101282</secondary_id>
    <nct_id>NCT02155608</nct_id>
  </id_info>
  <brief_title>Trigeminal Nerve Stimulation for ADHD</brief_title>
  <acronym>TNS for ADHD</acronym>
  <official_title>Developmental Pilot Study of External Trigeminal Nerve Stimulation for ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop external Trigeminal Nerve Stimulation (eTNS) as a
      potential nonmedication treatment for attention-deficit/hyperactivity disorder (ADHD).

      Study hypothesis address potential differences over 4 weeks of active vs. sham eTNS treatment
      on ADHD symptoms, measures of executive function, electroencephalography (EEG) profiles,
      other dimensional measures of height, weight, mood, anxiety, and sleep, and side effect
      profiles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This three-year developmental study is a double-blind randomized trial of active vs. inactive
      sham eTNS for ADHD, with four weeks acute treatment followed by an additional one week of
      clinical observation and testing after treatment cessation.

      The study will enroll 85-90 participants aged 8-12 years to achieve a completion target of
      N=36 for each study condition (total final N = 72). Participants will meet Diagnostic and
      Statistical Manual-5 (DSM-5) criteria for ADHD, any current presentation, as established by
      the Behavior Disorders Module of the Kiddie Schedule for Affective Disorders and
      Schizophrenia (KSADS-PL) and clinical interview.

      Other screening procedures include measures of ADHD symptom severity, other behavioral
      ratings, and cognitive assessments. Once inclusion/exclusion criteria have been reviewed and
      verified, participants in Phase 1A will have a pre-treatment visit to establish behavioral
      and cognitive baseline ratings and to obtain an EEG. Participants and parents will be
      instructed in the use of eTNS, and participants will begin use of the eTNS as directed during
      sleep each night. Participants will be randomized 1:1 to active or inactive sham eTNS.
      Participants, families, and most of the study team will remain blind to treatment assignment.
      Participants will have weekly assessments over the five-week study to assess behavioral,
      cognitive, and brain activation change and to monitor safety, tolerability, and compliance.
      Weekly ratings will be obtained from a parent, teacher, and clinician investigator. EEG will
      occur at baseline, end of treatment (week 4).

      In Phase 1B, all participants remain blinded for one week after cessation of the intervention
      and return for a final visit to assess residual effects of eTNS therapy vs. sham.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, sham-controlled.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD-IV Rating Scale (ADHD-RS)</measure>
    <time_frame>Change over baseline and weeks 1, 2, 3, 4 and 5.</time_frame>
    <description>A dimensional rating of ADHD symptoms, with scores ranging from 0 - 54, and higher scores indicating greater symptom severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Improvement (CGI-I)</measure>
    <time_frame>Change over weeks 1, 2, 3, 4, and 5 compared with baseline.</time_frame>
    <description>Categorical measure indicating degree improved or not improved compared with baseline for each treatment group. Minimum score = 1 (very much improved); Maximum score = 7 (very much worse). Results reflect number of participants stratified as &quot;Improved&quot; (CGI-I &lt;=2) or &quot;Not Improved&quot; (CGI-I &gt; 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Global Index - Parent Report</measure>
    <time_frame>Change over baseline and weeks 1, 2, 3, 4, 5.</time_frame>
    <description>Parent completed dimensional measure of ADHD symptoms, with score range from 0- 30, and higher scores indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Affective Reactivity Index (ARI) - Child</measure>
    <time_frame>Change over baseline and weeks 4 and 5.</time_frame>
    <description>A child completed dimensional measure of emotional reactivity, with scores ranging from 0-12, and higher scores indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Affective Reactivity Index (ARI) - Parent Report</measure>
    <time_frame>Change over baseline and weeks 4 and 5.</time_frame>
    <description>A parent completed dimensional measure of emotional reactivity, with scores ranging from 0-12, and higher scores indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional Anxiety Scale for Children (MASC) - Child Report</measure>
    <time_frame>Change over baseline and weeks 4 and 5.</time_frame>
    <description>A child completed rating of child anxiety, with scores ranging from 0-300, and higher scores indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional Anxiety Scale for Children (MASC) - Parent Report</measure>
    <time_frame>Change over baseline and weeks 4 and 5.</time_frame>
    <description>A parent completed rating of child anxiety, with scores ranging from 0-300, and higher scores indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>Change over baseline and weeks 1, 4, and 5.</time_frame>
    <description>A dimensional measure assessed in centimeters (cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Change over baseline and weeks 1, 4, and 5.</time_frame>
    <description>A dimensional measure assessed in kilograms (kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Change over baseline and weeks 1, 4, and 5.</time_frame>
    <description>A dimensional measure expressed in mm mercury (Hg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Change over baseline and weeks 1, 4, and 5.</time_frame>
    <description>A dimensional measure assessed in mm mercury (Hg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Change over baseline and weeks weeks 1, 4, and 5.</time_frame>
    <description>Heart rate in beats per minute (bpm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Depression Inventory (CDI)</measure>
    <time_frame>Change over baseline and weeks 4 and 5.</time_frame>
    <description>A child completed self-report dimensional measure of depressive symptoms, with range of scores from 0 to 54. Higher scores reflect increasing depression. Cutoff scores &lt; 17 to 20 are generally considered to be in the normative range. A score of 36 or higher reflects a relatively severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Global Index - Teacher</measure>
    <time_frame>Change over baseline and weeks 1, 2, 3, 4, 5.</time_frame>
    <description>Teacher completed dimensional measure of ADHD symptoms, with scores ranging from 0-30, and higher scores indicating more severe symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Affective Posner Task</measure>
    <time_frame>Baseline, and Weeks 1 and 4</time_frame>
    <description>A laboratory measure of frustration tolerance.</description>
  </other_outcome>
  <other_outcome>
    <measure>Attention Network Task (ANT) Response Inhibition</measure>
    <time_frame>Baseline, Weeks 1 and 4</time_frame>
    <description>A computer-administered laboratory measure of executive function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Spatial Working Memory (SWM)</measure>
    <time_frame>Baseline, Weeks 1 and 4</time_frame>
    <description>A computer-administered laboratory measure of executive function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Electroencephalography (EEG)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>A laboratory measure of cortical activity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Behavior Rating Inventory of Executive Functioning (BRIEF)</measure>
    <time_frame>Baseline, end of Weeks 4 and 5.</time_frame>
    <description>A parent completed rating of child executive function. Comprises 5 sub scales that measure various measures of behavior and cognition. Raw scores on each measure are converted to T scores ranging from 28 to 103, with higher scores indicating greater difficulties.</description>
  </other_outcome>
  <other_outcome>
    <measure>Children's Sleep Habits Questionnaire (CSHQ)</measure>
    <time_frame>Weekly for double-blind trial.</time_frame>
    <description>A parent completed 33-item scale to assess sleep related problems. Total scores range from 33 to 99 divided among 8 sub scales , with higher scores indicating more severe difficulties.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>Active eTNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham eTNS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active eTNS</intervention_name>
    <description>Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.</description>
    <arm_group_label>Active eTNS</arm_group_label>
    <other_name>Trigeminal Nerve Stimulation</other_name>
    <other_name>Monarch eTNS SystemTM (NeuroSigma, Inc., Los Angeles CA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham eTNS</intervention_name>
    <description>Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.</description>
    <arm_group_label>Sham eTNS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female children ages 8 to 12 years with DSM-5 ADHD, any current presentation,
             as determined by KSADS and clinical interview

          -  minimum scores of 12 on both the inattentive and hyperactive/impulsive subscales of
             the baseline ADHD-RS

          -  CGI-S score at baseline ≥ 4

          -  no current medication with CNS effects

          -  parents able and willing to monitor proper use of the stimulation device and complete
             all required rating scales

          -  estimated Full Scale IQ ≥ 85 based on WASI subtests

          -  parent and participant able to complete rating scales and other measures in English

          -  able to cooperate during EEG

        Exclusion Criteria:

          -  impaired functioning to a degree that requires immediate initiation of ADHD medication
             in the opinion of the parents and/or investigator

          -  current diagnosis of autism spectrum disorder or major depression

          -  history of lifetime psychosis, mania, seizure disorder or head injury with loss of
             consciousness

          -  baseline suicidality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James J McGough, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra K Loo, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Semel Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/30768393</url>
    <description>Pub Med Abstract</description>
  </link>
  <results_reference>
    <citation>McGough JJ, Sturm A, Cowen J, Tung K, Salgari GC, Leuchter AF, Cook IA, Sugar CA, Loo SK. Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2019 Apr;58(4):403-411.e3. doi: 10.1016/j.jaac.2018.11.013. Epub 2019 Jan 28.</citation>
    <PMID>30768393</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <results_first_submitted>February 26, 2019</results_first_submitted>
  <results_first_submitted_qc>March 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2019</results_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>James McGough</investigator_full_name>
    <investigator_title>Professor of Clinical Psychiatry</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>neuromodulation</keyword>
  <keyword>trigeminal nerve stimulation</keyword>
  <keyword>cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02155608/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 28, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02155608/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants enrolled between 04/2015 and 03/2017. Participants were recruited through community advertisements and internet postings.</recruitment_details>
      <pre_assignment_details>Potential participants underwent screening and those eligible returned for baseline assessment and randomization. Of 79 individuals screened, 64 met inclusion/exclusion criteria for participation. Two of these chose not to return after screening, most likely because they were only interested in ADHD assessment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active TNS</title>
          <description>Active TNS
Active TNS: Participants randomized to active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
        </group>
        <group group_id="P2">
          <title>Sham TNS</title>
          <description>Sham TNS
Sham TNS: Participants randomized to sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>1a: 4 Week Double Blind Sham Controlled</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>1b: 1 Week Blinded Post Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active eTNS</title>
          <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.</description>
        </group>
        <group group_id="B2">
          <title>Sham eTNS</title>
          <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.26" spread="1.39"/>
                    <measurement group_id="B2" value="10.50" spread="1.37"/>
                    <measurement group_id="B3" value="10.40" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADHD Subtype</title>
          <description>Subtypes listed (Combined, Inattentive, Hyperactive/Impulsive) reflect different subtypes of ADHD according to diagnostic criteria. They do not reflect any grading or measure of severity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Combined</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Inattentive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hyperactive/Impulsive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Full Scale IQ Estimate</title>
          <description>Based on the Wechsler Abbreviated Scales of Intelligence, 3rd Edition.</description>
          <units>IQ points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110.4" spread="12.3"/>
                    <measurement group_id="B2" value="107.3" spread="14.2"/>
                    <measurement group_id="B3" value="108.9" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADHD-Rating Scale Total Score</title>
          <description>A dimensional rating of ADHD symptoms with scores ranging from 0 to 54, with higher scores indicating greater severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.13" spread="6.28"/>
                    <measurement group_id="B2" value="32.83" spread="6.22"/>
                    <measurement group_id="B3" value="32.47" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression - Severity</title>
          <description>A categorical measure of severity ranging from 1 (&quot;Normal, not at all ill&quot;) to 7 (&quot;Among the most extremely ill patients.&quot;).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>4 (Moderately iIl)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Markedly ill)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ADHD-IV Rating Scale (ADHD-RS)</title>
        <description>A dimensional rating of ADHD symptoms, with scores ranging from 0 - 54, and higher scores indicating greater symptom severity.</description>
        <time_frame>Change over baseline and weeks 1, 2, 3, 4 and 5.</time_frame>
        <population>Data missing for some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open active eTNS in a 12 month extension period.</description>
          </group>
          <group group_id="O2">
            <title>Sham eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly active eTNS in a 12 month extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>ADHD-IV Rating Scale (ADHD-RS)</title>
          <description>A dimensional rating of ADHD symptoms, with scores ranging from 0 - 54, and higher scores indicating greater symptom severity.</description>
          <population>Data missing for some visits.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.12" spread="1.39"/>
                    <measurement group_id="O2" value="32.83" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.16" spread="1.39"/>
                    <measurement group_id="O2" value="28.53" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.74" spread="1.40"/>
                    <measurement group_id="O2" value="28.31" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.92" spread="1.42"/>
                    <measurement group_id="O2" value="28.78" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.38" spread="1.40"/>
                    <measurement group_id="O2" value="27.50" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="1.40"/>
                    <measurement group_id="O2" value="29.1" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parameterized in the model as a standard linear variable, time (ranging from baseline to 4 weeks) and a second variable, time2, defined as 0 at baseline and time past week 1 for subsequent weeks. The time2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.54</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .38, df = 1/228.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parameterized in the model as a standard linear variable, time (ranging from baseline to 4 weeks) and a second variable, time2, defined as 0 at baseline and time past week 1 for subsequent weeks. The time2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>p &lt; .05 for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F=39.97, df = 1/228</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parameterized in the model as a standard linear variable, time (ranging from baseline to 4 weeks) and a second variable, time2, defined as 0 at baseline and time past week 1 for subsequent weeks. The time2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.005</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 8.12, df = 1/228.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parameterized in the model as a standard linear variable, time (ranging from baseline to 4 weeks) and a second variable, time2, defined as 0 at baseline and time past week 1 for subsequent weeks. The time2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time2: F = 28.96, df = 1/228.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.02</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 6.23, df = 1/57.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.05</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = 4.18, df = 1/57.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.73</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .12, df = 1/57.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression - Improvement (CGI-I)</title>
        <description>Categorical measure indicating degree improved or not improved compared with baseline for each treatment group. Minimum score = 1 (very much improved); Maximum score = 7 (very much worse). Results reflect number of participants stratified as &quot;Improved&quot; (CGI-I &lt;=2) or &quot;Not Improved&quot; (CGI-I &gt; 2).</description>
        <time_frame>Change over weeks 1, 2, 3, 4, and 5 compared with baseline.</time_frame>
        <population>Data missing for some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.</description>
          </group>
          <group group_id="O2">
            <title>Sham eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression - Improvement (CGI-I)</title>
          <description>Categorical measure indicating degree improved or not improved compared with baseline for each treatment group. Minimum score = 1 (very much improved); Maximum score = 7 (very much worse). Results reflect number of participants stratified as &quot;Improved&quot; (CGI-I &lt;=2) or &quot;Not Improved&quot; (CGI-I &gt; 2).</description>
          <population>Data missing for some visits.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Assessed effects of group and time on categorical measure CGI-I from Baseline through Visit 4.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.003</p_value>
            <p_value_desc>p &lt; .05 for statistical significance</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Group: F = 8.75, df = 1/168.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Assessed effects of group and time on categorical measure CGI-I from Baseline through Visit 4.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.17</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Time: F = 1.69, df = 3/168.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Assessed effects of group on categorical measure CGI-I from at Visit 5 compared to baseline.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.46</p_value>
            <method>Chi-squared</method>
            <method_desc>Group: Chi-square = .53, df = 1.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conners Global Index - Parent Report</title>
        <description>Parent completed dimensional measure of ADHD symptoms, with score range from 0- 30, and higher scores indicating more severe symptoms.</description>
        <time_frame>Change over baseline and weeks 1, 2, 3, 4, 5.</time_frame>
        <population>Data missing for some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open active eTNS in a 12 month extension period.</description>
          </group>
          <group group_id="O2">
            <title>Sham eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly active eTNS in a 12 month extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Conners Global Index - Parent Report</title>
          <description>Parent completed dimensional measure of ADHD symptoms, with score range from 0- 30, and higher scores indicating more severe symptoms.</description>
          <population>Data missing for some visits.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="1.1"/>
                    <measurement group_id="O2" value="17.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="1.1"/>
                    <measurement group_id="O2" value="16.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="1.1"/>
                    <measurement group_id="O2" value="15.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="1.1"/>
                    <measurement group_id="O2" value="15.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="14.7"/>
                    <measurement group_id="O2" value="14.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="1.1"/>
                    <measurement group_id="O2" value="15.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parameterized in the model as a standard linear variable, time (ranging from baseline to 4 weeks) and a second variable, time2, defined as 0 at baseline and time past week 1 for subsequent weeks. The time2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.91</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F=.01; df =1/209.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parameterized in the model as a standard linear variable, time (ranging from baseline to 4 weeks) and a second variable, time2, defined as 0 at baseline and time past week 1 for subsequent weeks. The time2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.0004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F=13.03; df = 1/209.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parameterized in the model as a standard linear variable, time (ranging from baseline to 4 weeks) and a second variable, time2, defined as 0 at baseline and time past week 1 for subsequent weeks. The time2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.37</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .83; df = 1/209.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parameterized in the model as a standard linear variable, time (ranging from baseline to 4 weeks) and a second variable, time2, defined as 0 at baseline and time past week 1 for subsequent weeks. The time2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.007</p_value>
            <p_value_desc>Time2: F = 7.45, df = 1/209.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.67</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .19, df = 1/59.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.68</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = .17, df = 1/50.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.16</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 2.05, df = 1/50.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Affective Reactivity Index (ARI) - Child</title>
        <description>A child completed dimensional measure of emotional reactivity, with scores ranging from 0-12, and higher scores indicating greater severity.</description>
        <time_frame>Change over baseline and weeks 4 and 5.</time_frame>
        <population>Data missing for some visits</population>
        <group_list>
          <group group_id="O1">
            <title>Active eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open active eTNS in a 12 month extension period.</description>
          </group>
          <group group_id="O2">
            <title>Sham eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly active eTNS in a 12 month extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Affective Reactivity Index (ARI) - Child</title>
          <description>A child completed dimensional measure of emotional reactivity, with scores ranging from 0-12, and higher scores indicating greater severity.</description>
          <population>Data missing for some visits</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread=".5"/>
                    <measurement group_id="O2" value="4.5" spread=".5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread=".5"/>
                    <measurement group_id="O2" value="3.8" spread=".6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread=".5"/>
                    <measurement group_id="O2" value="3.5" spread=".6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.91</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .01, df = 1/56.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.15</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 2.12, df = .15</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.64</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .21, df = 1/56.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.66</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .20, df = 1/59.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.48</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = .50, df = 1/47.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.81</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .06, df = 1/47.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Affective Reactivity Index (ARI) - Parent Report</title>
        <description>A parent completed dimensional measure of emotional reactivity, with scores ranging from 0-12, and higher scores indicating greater severity.</description>
        <time_frame>Change over baseline and weeks 4 and 5.</time_frame>
        <population>Data missing for some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open active eTNS in a 12 month extension period.</description>
          </group>
          <group group_id="O2">
            <title>Sham eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly active eTNS in a 12 month extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Affective Reactivity Index (ARI) - Parent Report</title>
          <description>A parent completed dimensional measure of emotional reactivity, with scores ranging from 0-12, and higher scores indicating greater severity.</description>
          <population>Data missing for some visits.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread=".6"/>
                    <measurement group_id="O2" value="4.5" spread=".6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread=".6"/>
                    <measurement group_id="O2" value="3.6" spread=".7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread=".7"/>
                    <measurement group_id="O2" value="4.2" spread=".7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.89</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .02, df = 1/55.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.14</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 2.28, df = 1/55.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.80</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .06, df = .81.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.93</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .01, df = 1/58.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.15</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 2.22, df = 1/35.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.28</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 1.23, df = 1/35.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multidimensional Anxiety Scale for Children (MASC) - Child Report</title>
        <description>A child completed rating of child anxiety, with scores ranging from 0-300, and higher scores indicating greater severity.</description>
        <time_frame>Change over baseline and weeks 4 and 5.</time_frame>
        <population>Data missing from some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open active eTNS in a 12 month extension period.</description>
          </group>
          <group group_id="O2">
            <title>Sham eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly active eTNS in a 12 month extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Multidimensional Anxiety Scale for Children (MASC) - Child Report</title>
          <description>A child completed rating of child anxiety, with scores ranging from 0-300, and higher scores indicating greater severity.</description>
          <population>Data missing from some visits.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" spread="4.7"/>
                    <measurement group_id="O2" value="61.0" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="4.8"/>
                    <measurement group_id="O2" value="56.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="5.0"/>
                    <measurement group_id="O2" value="52.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.91</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .01; df = 1/46.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.11</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 2.62, df = 1/46.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.40</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .71; df = .40.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.49</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .48. df = 1/55.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.18</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 1.87, df = 1/55.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.72</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .13, df = 1/38.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multidimensional Anxiety Scale for Children (MASC) - Parent Report</title>
        <description>A parent completed rating of child anxiety, with scores ranging from 0-300, and higher scores indicating greater severity.</description>
        <time_frame>Change over baseline and weeks 4 and 5.</time_frame>
        <population>Data missing for some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open active eTNS in a 12 month extension period.</description>
          </group>
          <group group_id="O2">
            <title>Sham eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly active eTNS in a 12 month extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Multidimensional Anxiety Scale for Children (MASC) - Parent Report</title>
          <description>A parent completed rating of child anxiety, with scores ranging from 0-300, and higher scores indicating greater severity.</description>
          <population>Data missing for some visits.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="3.0"/>
                    <measurement group_id="O2" value="48.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="3.0"/>
                    <measurement group_id="O2" value="42.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="2.9"/>
                    <measurement group_id="O2" value="38.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.62</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F =.25, df = 1/53.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.06</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 3.58, df = 1/53.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.09</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 2.90, df 1/53.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.06</p_value>
            <p_value_desc>p &lt; .05 for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = 3.36, df = 1/58.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.05</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 4.20, df = 1/31.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.42</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .66, df = 1/31.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Height</title>
        <description>A dimensional measure assessed in centimeters (cm).</description>
        <time_frame>Change over baseline and weeks 1, 4, and 5.</time_frame>
        <population>Data missing for some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active TNS</title>
            <description>Active TNS
Active TNS: Participants randomized to active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
          </group>
          <group group_id="O2">
            <title>Sham TNS</title>
            <description>Sham TNS
Sham TNS: Participants randomized to sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
          </group>
        </group_list>
        <measure>
          <title>Height</title>
          <description>A dimensional measure assessed in centimeters (cm).</description>
          <population>Data missing for some visits.</population>
          <units>cm.</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.82" spread="1.78"/>
                    <measurement group_id="O2" value="141.45" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.79" spread="1.78"/>
                    <measurement group_id="O2" value="141.57" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.14" spread="1.78"/>
                    <measurement group_id="O2" value="142.31" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.58" spread="1.81"/>
                    <measurement group_id="O2" value="142.30" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.29</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = 0.29, df = 1/129.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.02</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 5.83, df = 1/129.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.31</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 1.03, df = 1/129.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.69</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .16, df = 1/59.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.33</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = .98, df = 1/54.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.35</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .88, df = 1/54.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <description>A dimensional measure assessed in kilograms (kg).</description>
        <time_frame>Change over baseline and weeks 1, 4, and 5.</time_frame>
        <population>Data missing for some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.</description>
          </group>
          <group group_id="O2">
            <title>Sham eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <description>A dimensional measure assessed in kilograms (kg).</description>
          <population>Data missing for some visits.</population>
          <units>kg.</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.83" spread="1.88"/>
                    <measurement group_id="O2" value="35.34" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.12" spread="1.88"/>
                    <measurement group_id="O2" value="35.58" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.65" spread="1.88"/>
                    <measurement group_id="O2" value="35.67" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.85" spread="1.93"/>
                    <measurement group_id="O2" value="35.71" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.21</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = 1.62, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.02</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 5.18, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.01</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 6.89, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.15</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F= 2.16, df = 1/59.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.05</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 4.15, df = 1/55.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.79</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .07, df = 1/55.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>A dimensional measure expressed in mm mercury (Hg).</description>
        <time_frame>Change over baseline and weeks 1, 4, and 5.</time_frame>
        <population>Data missing from some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active TNS</title>
            <description>Active TNS
Active TNS: Participants randomized to active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
          </group>
          <group group_id="O2">
            <title>Sham TNS</title>
            <description>Sham TNS
Sham TNS: Participants randomized to sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>A dimensional measure expressed in mm mercury (Hg).</description>
          <population>Data missing from some visits.</population>
          <units>mm Hg.</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.50" spread="2.26"/>
                    <measurement group_id="O2" value="106.10" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.03" spread="2.26"/>
                    <measurement group_id="O2" value="109.20" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.00" spread="2.26"/>
                    <measurement group_id="O2" value="107.79" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.26" spread="2.02"/>
                    <measurement group_id="O2" value="106.10" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.94</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .01, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.76</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = .09, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.39</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .75, df =1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.09</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = 3.06, df = 1/59.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.79</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = .07, df = 1/55.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.22</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 1.55, df = 1/55.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>A dimensional measure assessed in mm mercury (Hg).</description>
        <time_frame>Change over baseline and weeks 1, 4, and 5.</time_frame>
        <population>Data missing for some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active TNS</title>
            <description>Active TNS
Active TNS: Participants randomized to active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
          </group>
          <group group_id="O2">
            <title>Sham TNS</title>
            <description>Sham TNS
Sham TNS: Participants randomized to sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>A dimensional measure assessed in mm mercury (Hg).</description>
          <population>Data missing for some visits.</population>
          <units>mm Hg.</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.97" spread="1.66"/>
                    <measurement group_id="O2" value="63.61" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.69" spread="1.66"/>
                    <measurement group_id="O2" value="62.33" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.09" spread="1.66"/>
                    <measurement group_id="O2" value="61.01" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.30" spread="1.76"/>
                    <measurement group_id="O2" value="60.89" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.64</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .22, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.19</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 1.49, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.22</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 1.49, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.05</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = 3.95, df = 1/59.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.96</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 0.00, df = 1/55.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.92</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .01, df = 1/55.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse</title>
        <description>Heart rate in beats per minute (bpm).</description>
        <time_frame>Change over baseline and weeks weeks 1, 4, and 5.</time_frame>
        <population>Data missing for some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active TNS</title>
            <description>Active TNS
Active TNS: Participants randomized to active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
          </group>
          <group group_id="O2">
            <title>Sham TNS</title>
            <description>Sham TNS
Sham TNS: Participants randomized to sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse</title>
          <description>Heart rate in beats per minute (bpm).</description>
          <population>Data missing for some visits.</population>
          <units>bpm.</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.69" spread="2.27"/>
                    <measurement group_id="O2" value="76.70" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.91" spread="2.27"/>
                    <measurement group_id="O2" value="79.70" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.78" spread="2.27"/>
                    <measurement group_id="O2" value="75.18" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.42" spread="2.10"/>
                    <measurement group_id="O2" value="78.18" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.79</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .07, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.30</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 1.10, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.03</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 4.61, df = 1/128.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.14</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = 2.24, df = 1/59.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.82</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = .05, df = 1/55.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.07</p_value>
            <p_value_desc>p &lt; .05 for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 3.35, df = 1/55.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Children's Depression Inventory (CDI)</title>
        <description>A child completed self-report dimensional measure of depressive symptoms, with range of scores from 0 to 54. Higher scores reflect increasing depression. Cutoff scores &lt; 17 to 20 are generally considered to be in the normative range. A score of 36 or higher reflects a relatively severe depression.</description>
        <time_frame>Change over baseline and weeks 4 and 5.</time_frame>
        <population>Data missing for some visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Active eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open active eTNS in a 12 month extension period.</description>
          </group>
          <group group_id="O2">
            <title>Sham eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly active eTNS in a 12 month extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Children's Depression Inventory (CDI)</title>
          <description>A child completed self-report dimensional measure of depressive symptoms, with range of scores from 0 to 54. Higher scores reflect increasing depression. Cutoff scores &lt; 17 to 20 are generally considered to be in the normative range. A score of 36 or higher reflects a relatively severe depression.</description>
          <population>Data missing for some visits.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.14" spread="1.23"/>
                    <measurement group_id="O2" value="9.10" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.94" spread="1.22"/>
                    <measurement group_id="O2" value="8.21" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.88" spread="1.32"/>
                    <measurement group_id="O2" value="7.34" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.55</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .36, df = 1/52</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed model with group, time, and group-by-time interactions to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.34</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = .09, df = 1/52</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1 a: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interaction to test for treatment effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.81</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .06, df = 1/52</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.83</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = .05, df = 1/59</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.04</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 4.52, df = 1/43</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.73</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .12, df = 1/43</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conners Global Index - Teacher</title>
        <description>Teacher completed dimensional measure of ADHD symptoms, with scores ranging from 0-30, and higher scores indicating more severe symptoms.</description>
        <time_frame>Change over baseline and weeks 1, 2, 3, 4, 5.</time_frame>
        <population>Results may not be valid due to problems with data collection leading to substantial missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Active eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation.
Active eTNS: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.</description>
          </group>
          <group group_id="O2">
            <title>Sham eTNS</title>
            <description>Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation.
Sham eTNS: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Conners Global Index - Teacher</title>
          <description>Teacher completed dimensional measure of ADHD symptoms, with scores ranging from 0-30, and higher scores indicating more severe symptoms.</description>
          <population>Results may not be valid due to problems with data collection leading to substantial missing data.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.76" spread="1.32"/>
                    <measurement group_id="O2" value="15.15" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.86" spread="1.23"/>
                    <measurement group_id="O2" value="11.37" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.36" spread="1.27"/>
                    <measurement group_id="O2" value="15.64" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.56" spread="1.92"/>
                    <measurement group_id="O2" value="16.56" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.43" spread="1.69"/>
                    <measurement group_id="O2" value="14.53" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.54" spread="3.33"/>
                    <measurement group_id="O2" value="18.83" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parametrized in the model as a standard linear viable, time (ranging from baseline to 4 weeks) and a second variable, time2. defined as 0 at baseline and time past week 1 for subsequent weeks. The time 2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.21</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = 1.62, df = 1/58.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parametrized in the model as a standard linear viable, time (ranging from baseline to 4 weeks) and a second variable, time2. defined as 0 at baseline and time past week 1 for subsequent weeks. The time 2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.39</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = .74, df = 1/58.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parametrized in the model as a standard linear viable, time (ranging from baseline to 4 weeks) and a second variable, time2. defined as 0 at baseline and time past week 1 for subsequent weeks. The time 2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.18</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Time2: F = 1.88, df = 1/58.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1a: Outcomes were fitted via a mixed effects model with group-by-time interactions to test for treatment effects using a piecewise linear time trend. This was parametrized in the model as a standard linear viable, time (ranging from baseline to 4 weeks) and a second variable, time2. defined as 0 at baseline and time past week 1 for subsequent weeks. The time 2 coefficient represents the change in slope after the initial week.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.22</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = 1.56; df = 1/58.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.21</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Group: F = 1.72, df = 1/12.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <p_value_desc>Test not valid due to insufficient data.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Time: F = 0.00, df = 1/0.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase 1b: Outcomes were fitted via a mixed effects model with group, time, and group-by-time interactions to test for treatment effects between visits 4 and 5.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <p_value_desc>Test not valid due to insufficient data.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Group * time: F = .87, df = 1/0.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Affective Posner Task</title>
        <description>A laboratory measure of frustration tolerance.</description>
        <time_frame>Baseline, and Weeks 1 and 4</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Attention Network Task (ANT) Response Inhibition</title>
        <description>A computer-administered laboratory measure of executive function.</description>
        <time_frame>Baseline, Weeks 1 and 4</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Spatial Working Memory (SWM)</title>
        <description>A computer-administered laboratory measure of executive function.</description>
        <time_frame>Baseline, Weeks 1 and 4</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Electroencephalography (EEG)</title>
        <description>A laboratory measure of cortical activity.</description>
        <time_frame>Baseline and Week 4</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Behavior Rating Inventory of Executive Functioning (BRIEF)</title>
        <description>A parent completed rating of child executive function. Comprises 5 sub scales that measure various measures of behavior and cognition. Raw scores on each measure are converted to T scores ranging from 28 to 103, with higher scores indicating greater difficulties.</description>
        <time_frame>Baseline, end of Weeks 4 and 5.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Children's Sleep Habits Questionnaire (CSHQ)</title>
        <description>A parent completed 33-item scale to assess sleep related problems. Total scores range from 33 to 99 divided among 8 sub scales , with higher scores indicating more severe difficulties.</description>
        <time_frame>Weekly for double-blind trial.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data were collected over the double-blind study, beginning at baseline and then weekly for 5 weeks.</time_frame>
      <desc>Adverse events were solicited via a structured side effects questionnaire and open inquiry completed at baseline and each weekly visit during the double-blind phases.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active TNS</title>
          <description>Active TNS
Active TNS: Participants randomized to active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
        </group>
        <group group_id="E2">
          <title>Sham TNS</title>
          <description>Sham TNS
Sham TNS: Participants randomized to sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Rapid heartbeat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Stomachache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsy</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Slurred speech</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Frequent sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Difficulty finding words</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Trouble sleeping</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperactive</sub_title>
                <counts group_id="E1" events="27" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E2" events="40" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Feels strange</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Clenching teeth</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Wish to be dead.</sub_title>
                <description>Based on Columbia-Suicide Severity Rating Scale (C-SSRS)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Non-specific active suicidal thoughts</sub_title>
                <description>Based on Columbia-Suicide Severity Rating Scale (C-SSRS)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Active suicidal ideation without intent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Active suicidal ideation with some intent</sub_title>
                <description>Based on Columbia-Suicide Severity Rating Scale (C-SSRS)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Active suicidal ideation with active plan and intent</sub_title>
                <description>Based on Columbia-Suicide Severity Rating Scale (C-SSRS)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Frequent urination</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stuffy nose</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Trouble catching breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Insufficient data were collected with the Conners Teacher Report leading to small number of participants analyzed. Results are likely not valid.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James McGough, M.D.</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>310-794-7841</phone>
      <email>jmcgough@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

